Sygnature Extends Strategic Alliance with Cyprotex

The two firms have signed an extension of their strategic alliance for a further two years to accelerate their clients’ drug discovery projects into development.

UK-based drug discovery services provider Sygnature Discovery and preclinical discovery/development CRO Cyprotex Discovery Ltd. have signed an extension of their strategic alliance for a further two years.

The companies will expand their collaborative sales and marketing initiative to provide a fully-integrated discovery chemistry/ADME-Tox/DMPK service to accelerate their clients’ drug discovery projects into development.

Since the alliance began two years ago, both companies have expanded. Cyprotex acquired Apredica, an ADME-Tox specialist CRO, and the assets of Cellumen, including proprietary high content toxicology assays under the Cellciphr brand. Sygnature recently formed a strategic alliance with Saretius Ltd., a preclinical experimental services company offering models in pain,